"Citron's reports are a lot more fun to read than just about anything published by a mainstream Wall Street stock analyst."
-- Bloomberg News

Twitter
April 24, 2014
HomeReportsArchivesContact Us / SuggestionsLegal DisclaimerWho is Citron
 

Questcor is Deceiving the FDA and Investors

Posted in Citron Reports by Stocklemon on the March 14th, 2014

 

Citron Reports Further Results from Laboratory Testing:


Questcor is Deceiving the FDA and Investors

 

H.P. Acthar Gel’s Specified Active Ingredient Less Than 20% of the Label Specification

Bioactivity of Deamidated Hormone Fragment Far Lower than Pure ACTH

The FDA has been Notified

Citron reports on further lab data submitted to FDA, that the contents Questcor's only revenue-generating drug product, H.P. Acthar Gel, does not match its label or the official product insert the label.  Questcor spins one story for Wall Street, and another for the medical community, but the regulatory risk here cannot be overstated.  

For the Full Story, Click Here:

(As always, Citron recommends that you download the .PDF file locally, and click to follow the links.)

Plugging Into Some Reality: Fair Value of Plug Power is 50 Cents

Posted in Citron Reports by Stocklemon on the March 11th, 2014

Citron Research comments on the difference between a cult stock, a dream stock, and a casino stock.

Behind the moonshot chart, Citron examines a litany of Plug Power (NASDAQ:PLUG) management's broken promises, a doomed business model, and some true penny-stock capital raises just last year.  With no fundamental changes now or expected in its business model, this one has "bust" written all over it.

For the full story you won't read anywhere else, Click Here:

 

Next Page »


3 queries in 0.613 seconds